Drug Profile
Enfortumab vedotin - Astellas Pharma/Seagen
Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin; Enfortumab vedotin-ejfv; PADCEVLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Agensys; Seattle Genetics
- Developer Astellas Pharma; Astellas Pharma Global Development; Merck & Co; Seagen; Utah State University
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Urogenital cancer
- Phase III Bladder cancer
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 15 Feb 2024 Enfortumab vedotin receives priority review status for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Japan
- 31 Jan 2024 Preregistration for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Japan (IV) in January 2024
- 26 Jan 2024 Preregistration for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in European Union (IV)